Bedaquiline or delamanid for rifampin-resistant tuberculosis?

A comment published in The Lancet Respiratory Medicine describes how to choose between bedaquiline and delamanid for an individual patient with rifampin-resistant TB, and notes, "tuberculosis programmes should make both bedaquiline and delamanid available. Although there are no efficacy data to guide the choice of one agent over the other, there are clinical scenarios that favour either bedaquiline or delamanid, and there are some patients who will need both."

To download the full comment, click here.


Source: The Lancet Respiratory Medicine

To subscribe to the Weekly Newsletter of new posts, enter your email here:


By Erica Lessem, Vivian Cox, Jennifer Furin

Published: Sept. 7, 2017, 11:30 p.m.

Last updated: Sept. 8, 2017, 5:33 a.m.

Print Share